Prevalence of Mitral Regurgitation in Severe Aortic Stenosis

Severe aortic stenosis frequently coexists with mitral regurgitation in elderly individuals presenting with multivalvular heart disease. Furthermore, clinicians often encounter notable diagnostic hurdles when both valvular defects manifest simultaneously. Recent real-world findings from the large multicenter Egnite database highlight this critical clinical intersection. Specifically, the investigators examined over 2.9 million patients across 43 academic and community healthcare institutions. Within this extensive cohort, researchers identified 36,402 individuals presenting with confirmed severe aortic stenosis. Notably, approximately 14.8% of these patients exhibited concurrent moderate or greater mitral regurgitation. In addition, this double valve disease represents a highly vulnerable patient subset in routine cardiology practice. Patients with combined lesions typically present with advanced symptoms of congestive heart failure. Therefore, prompt clinical detection remains vital to prevent rapid ventricular decompensation and adverse remodeling. However, overlapping cardiac murmurs often complicate traditional bedside acoustic evaluations. Consequently, comprehensive transthoracic echocardiography serves as an indispensable tool for accurate diagnostic stratification. Early identification enables the heart team to stage anatomical severity precisely. Thus, establishing the true baseline regurgitant severity provides essential guidance for clinical decision-making.

Hemodynamic Interplay and Diagnostic Complexities

Valvular interdependence profoundly alters intracardiac hemodynamics when aortic outflow obstruction coincides with mitral incompetence. Specifically, severe aortic stenosis substantially elevates left ventricular systolic pressure throughout the cardiac cycle. Consequently, this intense afterload drives amplified retrograde volume across an incompetent mitral valve. As a result, Doppler echocardiography often overestimates the intrinsic anatomical severity of the regurgitant jet. Moreover, secondary functional mitral regurgitation frequently develops from adverse left ventricular dilation and papillary displacement. In contrast, primary organic disease arises directly from intrinsic leaflet calcification or myxomatous degeneration. Distinguishing between these distinct etiologies remains essential for determining optimal procedural strategy. Furthermore, significant mitral regurgitation reduces effective forward stroke volume across the narrowed aortic valve. Therefore, affected patients commonly present with paradoxical low-flow, low-gradient hemodynamics despite severe aortic narrowing. Consequently, standard transvalvular velocity gradients may inadvertently underestimate aortic stenosis severity. Clinicians must actively combine multimodality imaging, including transesophageal echocardiography and computed tomography. Ultimately, rigorous hemodynamic evaluation prevents underdiagnosis and avoids delayed intervention in vulnerable patients.

Mortality Burden of Undertreated Double Valve Disease

The clinical trajectory of untreated multivalvular disease reveals an alarming prognostic impact on patient survival. According to the Egnite registry, untreated patients experienced exceptionally steep mortality rates over two years. For instance, untreated individuals with isolated aortic stenosis and mild mitral regurgitation demonstrated a 36.8% two-year mortality. In contrast, two-year mortality escalated to 57.3% among untreated individuals with concurrent moderate mitral regurgitation. Furthermore, patients with untreated moderate-to-severe or severe regurgitation suffered an astounding 65.5% two-year all-cause mortality. Despite these severe risks, clinicians left 64.5% of patients with combined severe disease entirely untreated. In comparison, undertreatment occurred in 49.9% of individuals who presented with isolated aortic stenosis alone. Several factors drive this persistent therapeutic hesitation in real-world clinical practice. For example, physicians often perceive dual valve disease as an excessive risk in frail, elderly patients. Additionally, discordant hemodynamic findings frequently create diagnostic ambiguity and unwarranted clinical delay. Consequently, many high-risk patients miss essential interventional windows, resulting in preventable mortality.

Therapeutic Response Following Standalone TAVR

Transcatheter aortic valve replacement has transformed therapeutic approaches for patients with complex structural heart disease. Historically, surgeons recommended double valve surgery, which carried high perioperative morbidity and mortality. In recent years, standalone transcatheter aortic valve replacement has emerged as a preferred alternative. Interestingly, relieving left ventricular outflow obstruction triggers immediate and favorable hemodynamic unloading. Therefore, intracavitary pressures decline rapidly, which directly attenuates the transmittal regurgitant driving force. Consequently, secondary functional mitral regurgitation often improves dramatically without direct mechanical leaflet manipulation. The Egnite database robustly confirms this beneficial physiologic response in contemporary clinical practice. Specifically, among patients receiving transcatheter valve replacement alone, mitral regurgitation improved in 77.5% at 45 days. Moreover, nearly half of treated patients achieved regression to mild or trace regurgitation. These encouraging findings show that standalone transcatheter aortic valve replacement successfully treats most dual pathology candidates. Thus, percutaneous aortic replacement provides a safe, highly effective frontline strategy.

Clinical Implications for the Multidisciplinary Heart Team

These registry findings provide an actionable management roadmap for multidisciplinary heart teams. First, clinicians must proactively eliminate therapeutic delay in patients presenting with combined valvular disease. Because untreated multivalvular disease carries extraordinary two-year mortality, expectant watchful waiting poses significant danger. Therefore, rapid referral for interventional evaluation represents an essential clinical standard. Furthermore, heart teams should prioritize standalone transcatheter aortic valve replacement as the initial therapeutic step. Subsequently, clinicians must perform repeat echocardiographic surveillance at 30 to 45 days post-procedure. If significant symptomatic mitral regurgitation persists, operators can pursue staged transcatheter edge-to-edge repair. In addition, this staged percutaneous algorithm substantially avoids the surgical hazards of combined open replacement. In countries like India, expanding access to transcatheter valve interventions remains critically important. Ultimately, structured surveillance pathways will optimize functional outcomes and reduce avoidable deaths worldwide.

Frequently Asked Questions

How does severe aortic stenosis worsen concomitant mitral regurgitation?

Severe aortic outflow narrowing substantially increases left ventricular systolic pressures during systole. Consequently, this elevated intracavitary afterload forces a larger volume of blood backwards across the mitral valve into the left atrium. Furthermore, chronic left ventricular pressure overload induces adverse chamber dilation, wall remodeling, and papillary muscle displacement. As a result, these structural changes prevent proper leaflet coaptation, significantly exacerbating secondary mitral regurgitation and worsening overall patient hemodynamics.

Can TAVR alone resolve mitral regurgitation without a separate mitral procedure?

Yes, transcatheter aortic valve replacement alone significantly improves mitral regurgitation in approximately 78% of treated patients. Relieving the aortic outflow obstruction immediately reduces left ventricular systolic afterload, which decreases the driving gradient for retrograde flow. Additionally, reverse myocardial remodeling over subsequent weeks helps restore normal geometric leaflet coaptation. Consequently, nearly half of patients achieve reduction to mild or trace regurgitation at 45 days, effectively eliminating the need for upfront double valve surgery.

When should clinicians consider secondary transcatheter mitral repair after TAVR?

Clinicians should evaluate patients for staged transcatheter mitral repair if moderate-to-severe mitral regurgitation persists 30 to 60 days following successful TAVR. Furthermore, candidates must display persistent heart failure symptoms or ongoing progressive left ventricular chamber dilation despite optimal guideline-directed medical therapy. Heart teams carefully review repeat transthoracic echocardiography to assess mitral anatomy and confirm suitability for transcatheter edge-to-edge repair, ensuring timely secondary intervention for symptomatic relief and long-term cardiac protection.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Peterson BE et al. Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From Egnite Data. Circ Cardiovasc Interv. 2026 Sep 11. doi: 10.1161/CIRCINTERVENTIONS.126.016578. PMID: 42723621.


2. Nombela-Franco L et al. Clinical Outcome and Changes by Indication in Mitral Regurgitation After Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. 2014;63(24):2643-2658.


3. Otto CM et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227.